NRX Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
NRXP Nasdaq 8731 https://www.nrxpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NRX Pharmaceuticals Inc

NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement - Apr 18th, 2024 12:32 pm
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock - Apr 18th, 2024 12:30 pm
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock - Apr 17th, 2024 8:45 pm
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections - Apr 17th, 2024 12:30 pm
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) - Apr 15th, 2024 12:30 pm
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression - Apr 8th, 2024 12:30 pm
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Apr 1st, 2024 12:28 pm
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights - Mar 28th, 2024 12:03 pm
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing - Mar 28th, 2024 12:00 pm
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 - Mar 26th, 2024 8:03 pm
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK - Mar 25th, 2024 12:30 pm
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 - Mar 21st, 2024 8:02 pm
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders - Mar 21st, 2024 5:57 pm
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders - Mar 18th, 2024 12:30 pm
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales - Mar 12th, 2024 11:49 am
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) - Mar 11th, 2024 12:30 pm
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression - Mar 4th, 2024 1:30 pm
Positive Signs As Multiple Insiders Buy NRx Pharmaceuticals Stock - Mar 2nd, 2024 1:19 pm
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share - Mar 1st, 2024 1:30 pm
/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./ - Feb 27th, 2024 3:49 pm